Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.41 |
| ▸ | HTR3B | O95264 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | HTR3A | P46098 | 2/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31038164 | 0.77 | NPC1 (0.44) | ALDH1A1KMT2AMAPTKDM4ECYP1A2 | |
| SCHEMBL27730325 | 0.75 | ALDH1A1 (0.49) | ALDH1A1KMT2AMAPTKDM4EHRH3 | |
| SCHEMBL905287 | 0.71 | SMN1; SMN2 (0.44) | ALDH1A1KDM4ECYP1A2TDP1HSD17B10 | |
| SCHEMBL14919595 | 0.71 | NPC1 (0.49) | ALDH1A1KMT2AMAPTKDM4EHRH3 | |
| SCHEMBL2186020 | 0.69 | CDC7 (0.54) | ALDH1A1MAPTKDM4EHRH3HTR3E | |
| SCHEMBL3164215 | 0.67 | ALDH1A1 (0.55) | ALDH1A1KMT2AMAPTKDM4EHRH3 | |
| SCHEMBL10792966 | 0.67 | KMT2A (0.48) | ALDH1A1KMT2AMAPTKDM4EHRH3 | |
| SCHEMBL5167182 | 0.67 | ALDH1A1 (0.51) | ALDH1A1KMT2AMAPTKDM4EHRH3 | |
| SCHEMBL3749098 | 0.67 | COMT (0.49) | ALDH1A1MAPTHTR2CHRH4NPC1 | |
| Hydrochloric Acid SCHEMBL27959591 | 0.66 | ALDH1A1 (0.53) | ALDH1A1KMT2AMAPTKDM4EHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5621002-A | HAVING A MODIFIED COMPETITIVE ENZYME ACTIVITY INHBITOR LINKED TO A SPACER-DRUG; ENZYME CLEAVAGE AT A LOWER CONCENTRATION, I.E. LOW MICHAELIS-MENTEN CONSTANT(KM) | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1997-04-15 | — | — | US | claimed |
| EP-0615749-A2 | Use of NMDA antagonists for the treatment of pain | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-09-21 | — | — | EP | claimed |
| EP-0608893-A1 | Inhibiting the development of tolerance to and/or dependence on an additive substance | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-08-03 | — | — | EP | claimed |
| JP-2164878-A | — | — | None | — | — | JP | disclosed |
| US-20110300147-A9 | Inhibiting tumor cell invasion, metastasis and angiogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2010036977-A2 | COMBINATION THERAPIES WITH TOPIRAMATE FOR SEIZURES, RESTLESS LEGS SYNDROME, AND OTHER NEUROLOGICAL CONDITIONS | NEW ENGLAND MEDICAL CENTER HOSPITALS, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| US-20090175873-A1 | Inhibiting tumor cell invasion, metastasis and angiogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-07-09 | — | — | US | disclosed |
| EP-1976861-A2 | INHIBITING TUMOUR CELL INVASION, METASTASIS AND ANGIOGENESIS THROUGH TARGETTING LEGUMAIN | The Scripps Research Institute (US) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007064759-A2 | INHIBITING TUMOUR CELL INVASION, METASTASIS AND ANGIOGENESIS THROUGH TARGETTING LEGUMAIN | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-06-07 | — | — | WO | disclosed |
| US-RE39300-E1 | Inhibiting the development of tolerance to and/or dependence on an addictive substance | VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL COLLEGE OF VIRGINIA (US) | 2006-09-19 | — | — | US | disclosed |
| EP-0938305-B8 | METHOD OF ALLEVIATING PAIN BY MEANS OF COMBINING TRAMADOL WITH AN NMDA ANTAGONIST | ENDO PHARMACEUTICALS INC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-4999431-A | Reacting A Bromoquinoline Compound With Butyllithium And An N-Methyl-N-Methoxyalkanamide; Intermediates for Quinolyloxazole-2-ones | MERRELL DOW PHARMACEUTICALS (US) | 1991-03-12 | — | — | US | disclosed |
| US-4990519-A | Antiasthma, hypotensive agents, bronchodilator agents | MERRELL DOW PHARMACEUTICALS (US) | 1991-02-05 | — | — | US | disclosed |
| US-4990519-A | Antiasthma, hypotensive agents, bronchodilator agents | MERRELL DOW PHARMACEUTICALS (US) | 1991-02-05 | — | — | US | disclosed |
| US-4990519-A | Antiasthma, hypotensive agents, bronchodilator agents | MERRELL DOW PHARMACEUTICALS (US) | 1991-02-05 | — | — | US | disclosed |
| JP-H02164878-A | NOVEL QUINOLYLOXAZOL-2-ONES USEFUL AS PROTEINKINASE C INHIBITOR | MERRELL DOW PHARMACEUT INC | 1990-06-25 | — | — | JP | disclosed |
| EP-0365863-A2 | Novel quinolyloxazole-2-ones useful as proteinkinase C inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-05-02 | — | — | EP | disclosed |
| EP-0365863-A2 | Novel quinolyloxazole-2-ones useful as proteinkinase C inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-05-02 | — | — | EP | disclosed |
| US-4886811-A | HYPOTENSIVE AGENTS AND VASODILATORS | MERRELL DOW PHARMACEUTICALS (US) | 1989-12-12 | — | — | US | disclosed |
| US-4886811-A | HYPOTENSIVE AGENTS AND VASODILATORS | MERRELL DOW PHARMACEUTICALS (US) | 1989-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090175873-A1 | Inhibiting tumor cell invasion, metastasis and angiogenesis | MMP9, TIMP3, MMP3 | ALDH1A1 743/4885KMT2A 3581/4885MAPT 4380/4885 |
| US-20110300147-A9 | Inhibiting tumor cell invasion, metastasis and angiogenesis | MMP9, TIMP3, MMP3 | ALDH1A1 743/4885KMT2A 3581/4885MAPT 4380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.